ANDAs:Pharmaceutical Solid Polymorphism: Chemistry, Manufacturing, and Controls Information: Guidance for Industry
Detailed guidance document from FDA and regulatory agencies.
Document Details
Guidance Document
July 9, 2007
April 22, 2020
ea6f758d-a4f3-4afe-b529-2949f9e35169
Related Documents
180-Day Exclusivity When Multiple ANDAs Are Submitted on the Same Day
Guidance DocumentJuly 1, 2003Center for Drug Evaluation and Research
Nonclinical Safety Evaluation of Pediatric Drug Products
Guidance DocumentFebruary 15, 2006Center for Drug Evaluation and Research
User Fee Waivers for FDC and Co-Packaged HIV Drugs for PEPFAR
Guidance DocumentFebruary 8, 2007Center for Drug Evaluation and Research
Quick Actions
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust KeyPedia for their regulatory compliance needs.